Honz Pharmaceutical Co., Ltd., is a publicly listed company centered on medicines for children. It devotes to becoming the leading brand in the children’s healthcare industry in China.
Launched ‘Strategy of Children’s Healthcare’ and ‘Strategy of High Quality for Unmet Needs’, dedicated to building China’s leading children’s healthcare brand. Honz Pharma and Hengzhuo Technology agreed to collaborate in the cochlear implant market. Dependent on AIC Cochlear Implant Technology. The company also joined hands with Belgium’s Vésale Pharma to co-develop the market of probiotic health care food products. The company officially changed its name to Honz Pharmaceutical Co., Ltd.
Strengthened the sales team, and implemented streamlined marketing. The old sales and marketing team was expanded into Guangdong Kangda Marketing, Hainan Honz Marketing, and Beijing Xiangyun Marketing.
The Company acquired Guangdong Yuanning Pharmaceutical Co., Ltd., and initiated the investment of 220 million RMB in Zhongshan, Guangdong to build a state-of-the-artnew manufacturing base with full compliance with EU GMP standards.
The Company acquired Shenyang Yanfeng Pharmaceutical Co., Ltd., HebeiTianhe Pharmaceutical Group, and secured controlling shares of Beijing ShunxinXiangyun Pharmaceutical Co., Ltd.
The Company was publically listed on the Shenzhen Stock Exchange (stock code 300086), and became the first pharmaceutical company in Hainan Province listed on the GEM.
The Company finished restructuring its shareholding system, and changed its name to Hainan Honz Pharmaceutical Co., Ltd. At the same time，we established the business strategy of Focus on developing Children’s medicine.
The company confirmed operational strategy - ‘Make High Quality Medicines, Target the Professional Market’. Its products progressively covered the categories of anti-cold, antipyretics, antitussive, antidiarrheal, anti-allergy, anti-infection, and aged healthcare products. Medicines for children especially stand out of the market.
The Company proposed the marketing principle of “Manufacturer-Distributor Alliance for Win-Win Cooperation”, and made the marketing strategy to develop China’s medical market on the community level (third terminal).
The Company built a new plant in the Haikou Free Trade Zone, successfully obtained GMP certification for its solid dosage and powder production lines.
The company acquired Hainan Jiuzhou Pharmaceutical Co., Ltd., established Hainan ZhongruiHonz Pharmaceutical Co., Ltd., and started to transform itsmarketing and sales structure into amanufacturing-based one to lay the groundwork for the creation of its in-house independent brand.
The Company collaborated with Japan’s Daiichi Pharmaceutical Co., Ltd. (later acquired by Daiichi Sankyo Pharmaceutical Co., Ltd.),Germany’s Warsaw Pharmaceutical Co., Ltd., and established 16 offices around China committed to promoting medicines in hospital channels.
The Company became the first to implement a professional pharmaceutical agent system, and worked with Roche Switzerland, Serono Switzerland (Merck Serono), Novartis Switzerland and other world-renowned pharmaceutical companies to represent their partial sales business in China.
Mr. Hong Jiangyou founded Guangzhou Zhongrui Pharmaceutical Technology Co., Ltd., whose business covered pharmaceutical import trade and hospital-channeled sales. In the same year, the company started to work with Italian Lisa pharma S.p.A..